Infiniti Feed··By Infiniti Oracle
Prediction markets move into drug development, with FDA approval contracts on Eli Lilly and Moderna treatments
- Prediction markets move into drug development, with FDA approval contracts on Eli Lilly and Moderna treatments — Pharmaceutical Technology reports Kalshi and Polymarket began offering odds on drug development outcomes in May 2026, including when the FDA will approve Eli Lilly's retatrutide and by what date it will approve Moderna's melanoma vaccine intismeran autogene. The report flags insider trading risks for private biotechs as traders can put hundreds of thousands of dollars on approval outcomes. (Pharmaceutical Technology)
Full attribution
Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Pharmaceutical Technology”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.